UPDATE: Vericel (VCEL) Reports Q4 Loss of $0.14/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. CSX
7. LRCX
8. MRK
9. LVS
10. SAP

Go back to UPDATE: Vericel (VCEL) Reports Q4 Loss of $0.14/Share

Vericel Reports Fourth-Quarter and Year-End 2016 Financial Results

March 10, 2017 7:15 AM EST

Record Revenues of $16.5 Million Reported for the Fourth Quarter

Conference Call Today at 8:00am Eastern Time

CAMBRIDGE, Mass., March 10, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ: VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2016.

Total net revenues for the quarter ended December 31, 2016 were approximately $16.5 million and included approximately $12.7 million of Carticel® (autologous cultured chondrocytes) net revenues and approximately $3.8... More